Loading organizations...

§ Private Profile · 9 Laboratory Drive, Suite 267, Durham, North Carolina
Meiogenix is a technology company.
Meiogenix is an agriculture biotech company developing proprietary breeding technologies based on precise, targeted recombination and chromosome editing. Their innovative approach accelerates genetic gain and advanced variety development by unlocking natural genetic diversity within crops. This empowers breeders to create elite varieties that enhance productivity and disease resilience, addressing global agricultural demands.
Founded in 2010 by Giacomo Bastianelli, Meiogenix stemmed from the insight that targeted genetic recombination improves crop breeding. This scientific foundation advanced the company beyond conventional methods. Luc Mathis guided its early growth as CEO before Ricardo Garcia de Alba assumed leadership, driving its strategic direction.
Meiogenix partners with breeders, licensing its recombination platform to enhance both specialty and major field crops. The company's vision is to integrate its technology into every breeder's toolkit, harnessing genetic diversity to transform global agriculture and ensure a sustainable, secure agricultural future.
Meiogenix has raised $12.0M across 1 funding round.
Meiogenix has raised $12.0M in total across 1 funding round.
Meiogenix has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $12M Series A | Michael Krel | Genoa Ventures, Tekfen Ventures, TAZ Patel, Alexandria Venture Investments, Bpifrance, Casdin Capital | Announced |
Meiogenix is an agriculture biotechnology company that commercializes a proprietary chromosome editing / targeted recombination platform to accelerate precision breeding and unlock hidden genetic diversity in crops for breeders and agribusiness partners[4][5].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Meiogenix positions itself as a platform provider that could materially speed plant breeding by unlocking hidden diversity through targeted recombination; the company’s RTP expansion, patents and early collaborations suggest momentum, but broad industry adoption will hinge on replicated success in large‑scale breeding programs and commercially meaningful licensing deals[2][1][5].
Meiogenix has raised $12.0M in total across 1 funding round.
Meiogenix's investors include Michael Krel, Genoa Ventures, Tekfen Ventures, Taz Patel, Alexandria Venture Investments, Bpifrance, Casdin Capital.